Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens

Cancer

Volumn 115, Issue 1, 2009, Pages 101-106

  Verma, Dushyant ^a   O'Brien, Susan ^a   Thomas, Deborah ^a   Faderl, Stefan ^a   Koller, Charles ^a   Pierce, Sherry ^a   Kebriaei, Partow ^a   Garcia Manero, Guillermo ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Hyper CVAD; Secondary acute myelogenous leukemia; Secondary myelodysplastic syndrome

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARSENIC TRIOXIDE; ASPARAGINASE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTHRACYCLINE ANTIBIOTIC AGENT; DECITABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; FEMALE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE; ACUTE MYELOBLASTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG RESPONSE; DRUG SAFETY; METASTASIS; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; VINCRISTINE;

EID: 58949094403     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24005     Document Type: Article

References (15)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
2. Hijiya N, Hudson MM, Lensing S, et al Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007;297:1207-1215.
3. Bhatia S, Sather HN, Pabustan OB, Trigg ME, Gaynon PS, Robison LL. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood. 2002;99:4257-4264.
4. Loning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood. 2000;95: 2770-2775.
5. Winick NJ, McKenna RW, Shuster JJ, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol. 1993;11:209-217.
6. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;325:1330-1336.
7. Pui CH, Ribeiro H, Hancock M, et al. Acute myeloid leukemia in children treated with epipophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682-1687.
8. Pui CH, Behm FG, Raimondi SC, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989;321:136-142.
9. Tavernier E, Le QH, de Botton S, et al. Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials. Cancer. 2007;110:2747-2755.
10. Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007;25:3871-3876.
11. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99:196-205.
12. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol. 1998;124:207-214.
13. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995;86:3542-3552.
14. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788-2801.
15. Gill S, Lane SW, Crawford J, et al. Prolonged haematologic toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Ann Hematol. 2008;87:727-734.